PL3096759T3 - Preparaty pridopidyny o zmodyfikowanym uwalnianiu - Google Patents
Preparaty pridopidyny o zmodyfikowanym uwalnianiuInfo
- Publication number
- PL3096759T3 PL3096759T3 PL15740303T PL15740303T PL3096759T3 PL 3096759 T3 PL3096759 T3 PL 3096759T3 PL 15740303 T PL15740303 T PL 15740303T PL 15740303 T PL15740303 T PL 15740303T PL 3096759 T3 PL3096759 T3 PL 3096759T3
- Authority
- PL
- Poland
- Prior art keywords
- pridopidine
- release formulations
- modified release
- modified
- formulations
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- YGKUEOZJFIXDGI-UHFFFAOYSA-N pridopidine Chemical compound C1CN(CCC)CCC1C1=CC=CC(S(C)(=O)=O)=C1 YGKUEOZJFIXDGI-UHFFFAOYSA-N 0.000 title 1
- 229950003764 pridopidine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Inorganic Chemistry (AREA)
- Botany (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Oil, Petroleum & Natural Gas (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461930358P | 2014-01-22 | 2014-01-22 | |
| US201462050626P | 2014-09-15 | 2014-09-15 | |
| PCT/US2015/012248 WO2015112601A1 (en) | 2014-01-22 | 2015-01-21 | Modified release formulations of pridopidine |
| EP15740303.1A EP3096759B1 (en) | 2014-01-22 | 2015-01-21 | Modified release formulations of pridopidine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3096759T3 true PL3096759T3 (pl) | 2022-06-13 |
Family
ID=53543863
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15740303T PL3096759T3 (pl) | 2014-01-22 | 2015-01-21 | Preparaty pridopidyny o zmodyfikowanym uwalnianiu |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US20150202302A1 (pl) |
| EP (2) | EP3096759B1 (pl) |
| JP (2) | JP6949487B2 (pl) |
| KR (1) | KR102479759B1 (pl) |
| CN (1) | CN106170287A (pl) |
| AU (1) | AU2015209411A1 (pl) |
| CA (1) | CA2937243C (pl) |
| CL (1) | CL2016001874A1 (pl) |
| DK (1) | DK3096759T3 (pl) |
| EA (1) | EA201691454A1 (pl) |
| ES (1) | ES2911800T3 (pl) |
| HU (1) | HUE058288T2 (pl) |
| IL (2) | IL246598B (pl) |
| MX (1) | MX377576B (pl) |
| PE (1) | PE20161220A1 (pl) |
| PL (1) | PL3096759T3 (pl) |
| TW (1) | TW201605446A (pl) |
| UA (1) | UA122053C2 (pl) |
| UY (1) | UY35962A (pl) |
| WO (1) | WO2015112601A1 (pl) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| EP2611759A1 (en) | 2010-09-03 | 2013-07-10 | Ivax International Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| UY34503A (es) | 2011-12-08 | 2013-07-31 | Ivax Int Gmbh | ?sal de bromhidrato de pridopidina? |
| WO2014205229A1 (en) | 2013-06-21 | 2014-12-24 | IVAX International GmbH | Use of high dose pridopidine for treating huntington's disease |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| MX377576B (es) | 2014-01-22 | 2025-03-04 | Prilenia Neurotherapeutics Ltd | Formulaciones de pridopidina de liberación modificada. |
| TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| US9796673B2 (en) | 2014-12-22 | 2017-10-24 | Teva Pharmaceuticals International Gmbh | L-tartrate salt of pridopidine |
| WO2016138130A1 (en) | 2015-02-25 | 2016-09-01 | Teva Pharmaceuticals International Gmbh | Use of pridopidine to improve cognitive function and for treating alzheimer's disease |
| US11471449B2 (en) | 2015-02-25 | 2022-10-18 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to improve cognitive function and for treating Alzheimer's disease |
| AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
| WO2017015615A1 (en) * | 2015-07-22 | 2017-01-26 | Teva Pharmaceuticals International Gmbh | Pridopidine base formulations and their use |
| CA3015512C (en) | 2016-02-24 | 2024-01-16 | Teva Pharmaceuticals International Gmbh | Treatment of neurodegenerative eye disease using pridopidine |
| CA3035092C (en) | 2016-08-24 | 2022-05-31 | Prilenia Therapeutics Development Ltd. | Use of pridopidine for treating functional decline |
| CA3035099C (en) * | 2016-08-24 | 2023-01-17 | Prilenia Therapeutics Development Ltd. | Use of pridopidine for treating dystonias |
| DK4005570T3 (da) * | 2016-09-16 | 2024-08-19 | Prilenia Neurotherapeutics Ltd | Pridopidin til anvendelse behandling af retts syndroe |
| US12102627B2 (en) | 2016-09-16 | 2024-10-01 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating rett syndrome |
| AU2018210145B2 (en) | 2017-01-20 | 2023-06-29 | Agency For Science, Technology And Research | Use of pridopidine for the treatment of fragile X syndrome |
| BR112020003119A2 (pt) | 2017-08-14 | 2020-10-13 | Prilenia Neurotherapeutics Ltd. | método de tratamento de esclerose lateral amiotrófica com pridopidina |
| EP3675830A1 (en) * | 2017-08-30 | 2020-07-08 | Prilenia Neurotherapeutics Ltd. | High concentration dosage forms of pridopidine |
| US12036213B2 (en) | 2017-09-08 | 2024-07-16 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| EP3678664A1 (en) | 2017-09-08 | 2020-07-15 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| KR20200056071A (ko) | 2018-11-14 | 2020-05-22 | 한화토탈 주식회사 | 내열성, 강성 및 용융 강도가 우수한 폴리올레핀 수지 조성물 |
| EP3920924A4 (en) | 2019-02-04 | 2022-11-16 | Prilenia Neurotherapeutics Ltd. | LOW-DOSE PRIDOIDIN FOR THE TREATMENT OF PARKINSON'S DISEASE AND OTHER PARKINSONIC-RELATED DISEASES |
| WO2024258929A1 (en) * | 2023-06-12 | 2024-12-19 | Unravel Biosciences, Inc. | Methods for treating diseases associated with taf1 loss of function |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4020983B2 (ja) * | 1995-07-07 | 2007-12-12 | 帝國製薬株式会社 | 持続性製剤およびその製法 |
| SE9904724D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
| RU2277416C2 (ru) * | 2000-03-21 | 2006-06-10 | Ниппон Синяку Ко., Лтд. | Препараты для перорального введения с замедленным высвобождением |
| AR030557A1 (es) * | 2000-04-14 | 2003-08-27 | Jagotec Ag | Una tableta en multicapa de liberacion controlada y metodo de tratamiento |
| GB0125088D0 (en) * | 2001-10-18 | 2001-12-12 | Smithkline Beecham Cork Ltd | New use |
| BRPI0414082A (pt) * | 2003-09-02 | 2006-10-24 | Pfizer Prod Inc | formas de dosagem de liberação sustentada de ziprasidona |
| ES2659577T3 (es) | 2004-10-13 | 2018-03-16 | Teva Pharmaceuticals International Gmbh | Proceso para la síntesis de 4-(3-metanosulfonilfenil)-1-N-propil-piperidina |
| US20110206782A1 (en) * | 2010-02-24 | 2011-08-25 | Auspex Pharmaceuticals, Inc. | Piperidine modulators of dopamine receptor |
| UY34503A (es) * | 2011-12-08 | 2013-07-31 | Ivax Int Gmbh | ?sal de bromhidrato de pridopidina? |
| US20130267552A1 (en) | 2012-04-04 | 2013-10-10 | IVAX International GmbH | Pharmaceutical compositions for combination therapy |
| WO2014205229A1 (en) * | 2013-06-21 | 2014-12-24 | IVAX International GmbH | Use of high dose pridopidine for treating huntington's disease |
| MX377576B (es) | 2014-01-22 | 2025-03-04 | Prilenia Neurotherapeutics Ltd | Formulaciones de pridopidina de liberación modificada. |
-
2015
- 2015-01-21 MX MX2016009427A patent/MX377576B/es active IP Right Grant
- 2015-01-21 EP EP15740303.1A patent/EP3096759B1/en active Active
- 2015-01-21 CA CA2937243A patent/CA2937243C/en active Active
- 2015-01-21 CN CN201580005659.9A patent/CN106170287A/zh active Pending
- 2015-01-21 ES ES15740303T patent/ES2911800T3/es active Active
- 2015-01-21 EP EP22163271.4A patent/EP4049657A1/en not_active Withdrawn
- 2015-01-21 AU AU2015209411A patent/AU2015209411A1/en not_active Abandoned
- 2015-01-21 KR KR1020167022884A patent/KR102479759B1/ko active Active
- 2015-01-21 US US14/601,920 patent/US20150202302A1/en not_active Abandoned
- 2015-01-21 UA UAA201608936A patent/UA122053C2/uk unknown
- 2015-01-21 WO PCT/US2015/012248 patent/WO2015112601A1/en not_active Ceased
- 2015-01-21 PL PL15740303T patent/PL3096759T3/pl unknown
- 2015-01-21 DK DK15740303.1T patent/DK3096759T3/da active
- 2015-01-21 EA EA201691454A patent/EA201691454A1/ru unknown
- 2015-01-21 HU HUE15740303A patent/HUE058288T2/hu unknown
- 2015-01-21 PE PE2016001263A patent/PE20161220A1/es not_active Application Discontinuation
- 2015-01-21 JP JP2016547847A patent/JP6949487B2/ja active Active
- 2015-01-22 UY UY0001035962A patent/UY35962A/es not_active Application Discontinuation
- 2015-01-22 TW TW104102153A patent/TW201605446A/zh unknown
-
2016
- 2016-07-04 IL IL246598A patent/IL246598B/en active IP Right Grant
- 2016-07-22 CL CL2016001874A patent/CL2016001874A1/es unknown
-
2018
- 2018-08-28 US US16/115,105 patent/US20190209542A1/en not_active Abandoned
-
2019
- 2019-09-30 JP JP2019179329A patent/JP7266298B2/ja active Active
-
2021
- 2021-01-28 IL IL280485A patent/IL280485B2/en unknown
-
2023
- 2023-10-23 US US18/491,871 patent/US20240041855A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL280485A (en) | Sustained-release pridopidine preparations | |
| IL250511A0 (en) | Crystalline forms of ibrutinib | |
| PL3137060T5 (pl) | Kompozycje zawiesinowe o przedłużonym uwalnianiu | |
| PL3099381T3 (pl) | Kompozycje środków zapachowych o przedłużonym uwalnianiu | |
| PT3102555T (pt) | Composições de compostos e seus usos | |
| GB201404139D0 (en) | Sustained release buprenorphine solution formulations | |
| IL252062A0 (en) | Transdermal compositions | |
| PT3474822T (pt) | Formulações de brincidofovir | |
| SI3524234T1 (sl) | Trdne oblike sofosbuvira | |
| GB201419091D0 (en) | Formulations | |
| IL248223B (en) | Compositions of vaccine | |
| PL3223837T3 (pl) | Lactobacillus do zastosowania jako probiotyk | |
| GB201419261D0 (en) | Formulations | |
| IL246979A0 (en) | Crystalline forms of sofosbuvir | |
| SG11201803156TA (en) | Sustained release formulations of local anesthetics | |
| PL3142641T3 (pl) | Preparaty do leczenia nadczynności tarczycy | |
| IL247828A0 (en) | Progesterone compounds | |
| IL246569A0 (en) | Solid forms of tenofovir | |
| IL249130B (en) | Preparation of piperidine-4-carbothioamide | |
| TWI561205B (en) | Quick release structure of electrosurgical unit | |
| HK1228789A1 (en) | Modified release formulations of pridopidine | |
| IL249332A0 (en) | Crystalline forms of sofosbuvir | |
| GB201412359D0 (en) | Composition of objects | |
| GB201412089D0 (en) | Composition of objects | |
| GB201418410D0 (en) | use of compositions of matter |